Impact BioMedical, INC. Amortization
Impact BioMedical, INC. (IBO) reported Amortization of $835.00 thousand for the 9-month period ending 2024-09-30, per its 10-Q filed 2024-11-12.
Financial Statements › Cash Flow › Operating Activities
us-gaap:AdjustmentForAmortization · last filed 2024-11-12
- Impact BioMedical, INC. amortization for the quarter ending 2024-09-30 was $279.00K, a 0.00% change year-over-year.
- Impact BioMedical, INC. amortization for the quarter ending 2024-06-30 was $278.00K, a 0.00% change year-over-year.
- Impact BioMedical, INC. amortization for the quarter ending 2024-03-31 was $278.00K, a 0.00% change year-over-year.
- Impact BioMedical, INC. amortization for the quarter ending 2023-09-30 was $279.00K.
| Period end | Amortization 3 month | Amortization 6 month | Amortization 9 month |
|---|---|---|---|
| 2024-09-30 | $279.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $557.00K derived: sum of 2 quarters · filed 2024-11-12 | $835.00K 10-Q · filed 2024-11-12 |
| 2024-06-30 | $278.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | $556.00K 10-Q · filed 2024-08-13 | |
| 2024-03-31 | $278.00K 10-Q · filed 2024-05-10 | ||
| 2023-09-30 | $279.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $557.00K derived: sum of 2 quarters · filed 2024-11-12 | $835.00K 10-Q · filed 2024-11-12 |
| 2023-06-30 | $278.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | $556.00K 10-Q · filed 2024-08-13 | |
| 2023-03-31 | $278.00K 10-Q · filed 2024-05-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |